Understanding Preclinical Alzheimer’s Disease
Recent advancements in medical imaging have revolutionized the identification of preclinical Alzheimer’s disease, a task that was once exceptionally challenging. The implementation of innovative imaging techniques has enabled technicians and researchers to detect deposits of the protein amyloid-beta in the brain, which serves as a key indicator of Alzheimer’s disease and disrupts the brain’s communication system. Additionally, genetic tests can now provide valuable insight into an individual’s likelihood of developing the condition, particularly if there is a family history of the disease.
Stage Two: Mild Cognitive Impairment or Very Mild Decline
During the second stage of Alzheimer’s disease, known as mild cognitive impairment or very mild decline, individuals and their loved ones may start observing slight changes in their thinking ability and memory. These changes often manifest as occasional memory lapses regarding recent events, appointments, or conversations. Additionally, individuals may struggle with remembering the steps to complete a task or have difficulty estimating the time required for certain activities. Although these symptoms may not yet significantly impact daily life, they can be concerning for both the person experiencing them and their support system.